Table 1.

Comparison of immune cell marker gene expression on day 13 vs. day 12. Changes in innate immune cell marker genes in CPA/6d-treated tumors on day 13 (i.e., one day after a third CPA injection) compared to day 12 (i.e., 6 days after 2 injections of CPA), based on data in Fig. 2. Values shown in columns 3 and 4 are fold-changes ± SE in the expression level of each immune marker gene compared to drug-free (untreated control) tumors. The percentage values shown in column 5 indicate the extent to which the immune marker gene declines within one day of a third CPA injection given on day 12, and is calculated using the formula: 100% × (day12 - day13)/day12. The significance of the change was assessed by 1-tailed t-test. NS, not significant (p>0.05).

Cell type	Genes	Day 12 (2-CPA) fold-change	Day 13 (3-CPA) fold-change	Day 13 vs day 12 % decrease	p-value
NK cells	Nkp46	4.8 ± 1.0	1.2 ± 0.4	75.4	<0.01
	Nkg2d	6.0 ± 1.1	2.3 ± 0.5	61.5	<0.02
NK cell activation	Prf1	4.1 ± 1.2	1.6 ± 0.6	60.1	0.06
	Gzmb	5.5 ± 1.5	2.2 ± 0.6	59.3	<0.05
Dendritic cells	Cd74	5.2 ± 0.8	4.5 ± 1.0	13.7	NS
	Cd207	2.3 ± 0.9	3.0 ± 0.8	−29.9	NS
Macrophages	Cd68	5.2 ± 0.7	4.7 ± 0.4	10.9	NS
	Emr1	13.2 ± 2.8	9.1 ± 0.8	31.4	NS